# CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Source: https://onco.cc/trials/nct05440786/  
OnCo record `nct05440786` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abemaciclib and Temozolomide in ewing sarcoma, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma is a phase 2 interventional study registered as NCT05440786 by Eli Lilly and Company, with 46 participants enrolled, started 2022-09-20 and due to reach its primary completion in 2025-01-15. Interventions recorded: Abemaciclib, Irinotecan and Temozolomide. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05440786
- Phase: 2
- Setting: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma
- Sponsor: Eli Lilly and Company
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT05440786: https://clinicaltrials.gov/study/NCT05440786

## Connected records

- cancers: [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct05440786.json